Skip to main content

Table 4 Eligibility criteria to gadolinium contrast-enhanced magnetic resonance imaging at the Leeds Musculoskeletal Biomedical Research Unit

From: The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes

Absence of previous reactions to gadolinium contrast

Absence of concomitant allergies to multiple drugs

Absence of severe allergies to drugs or food

Absence of a pacemaker

Absence of metallic implants (e. g.: cardiac valves, joint prostheses, stents, cochlear implants)

Absence of metallic fragments in the eyes

Absence of unstable bronchial asthma

  1. All criteria must be satisfied to fulfil eligibility